QMSMEDI · NSE
QMS Medical Allied Services Limited
₹138.13
+4.71% (+₹6.21)
Prev. close
₹131.92
Volume
1,24,582
Delivery %
72.4%
As of
17 Aug 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About QMS Medical Allied Services Limited
QMS Medical Allied Services Limited distributes medical and healthcare devices in India. The company also manufactures and sells glucometers, pulse oximeters, IR thermometers, BP monitors, anatomy sets, neurology kits, orthopedic aids, and weighing scales, etc.; and operates QMSMEDS, an e-commerce platform that sells healthcare devices of various brands. In addition, the company provides diagnostic and patient management services, including ambulatory blood pressure tracking, continuous blood glucose and blood pressure/glucose monitoring, tonometry, and HbA1C services. Further, it offers Educamedics, which provides customized scientific content in the form of conferences, online courses, webinars, recorded lectures, and others. Additionally, the company offers chemical and chemical products, pharmaceuticals, and medicinal chemical and botanical products. QMS Medical Allied Services Limited was founded in 1994 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Mr. Mahesh Pahalraj Makhija
Headquarters
Mumbai
Website
qmsmas.comExchange
View on NSE ↗Key stats
Market cap
₹249.40 Cr
P/E ratio (TTM)
25.6
Dividend yield
0.38%
EPS (TTM)
₹5.40
Beta (1Y · daily vs NIFTY 50)
0.50
Beta (5Y · monthly vs NIFTY 50)
1.18
Shares float
92.47 L
EPS · quarter ended Mar 2026
₹0.89
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own reporting calendar.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹104.04 Cr | ₹122.13 Cr | ₹156.01 Cr | ₹172.88 Cr | |
| EBITDA | — | ₹11.78 Cr | ₹18.80 Cr | ₹27.12 Cr | ₹26.93 Cr |
| — | ₹6.38 Cr | ₹9.00 Cr | ₹13.70 Cr | ₹11.92 Cr | |
| Diluted EPS | ₹5.92 | ₹3.86 | ₹4.98 | ₹6.65 | — |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹117.74 Cr | ₹135.32 Cr | ₹189.79 Cr | ₹212.85 Cr | |
| Total debt | ₹25.52 Cr | ₹34.55 Cr | ₹60.29 Cr | ₹74.48 Cr |
| Stockholders' equity | ₹70.40 Cr | ₹78.51 Cr | ₹89.71 Cr | ₹104.19 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| — | — | ₹20.12 Cr | ₹19.44 Cr | |
| Investing cash flow | — | — | ₹-45.49 Cr | ₹-20.42 Cr |
| — | — | ₹25.89 Cr | ₹1.11 Cr | |
| Capital expenditure | — | — | ₹-48.33 Cr | ₹-5.79 Cr |
| End cash position | — | — | ₹1.06 Cr | ₹1.19 Cr |
Operating cash flow, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Oct 22–Mar 23(3Q) | Sep 23–Mar 24(2Q) | Sep 24–Jun 25(3Q) | Sep 25 | Sep 25–Jun 26(3Q) |
|---|---|---|---|---|---|
| Promoter | 73.67% | 73.67% | 73.67% | 68.07% | 68.11% |
| Public | 26.33% | 26.34% | 26.33% | 31.93% | 31.89% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| QMS Medical Allied Services Limited | ₹249.40 Cr | ₹138.13 | 25.6 | 2.39 | 11.4% | 0.71 | +10.8% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.